Bryon Johnson, PhD, is a Professor of Medicine in the Division of Hematology and Oncology at the Medical College of Wisconsin (MCW). Dr. Johnson’s career over the last 25 years has focused on understanding the biology and immunology of cancer, and uncovering new immune-based approaches to treat various cancers. His translational research has centered on combining the following approaches to improve the use of cancer immunotherapy for treating both solid tumors and blood cancers: (1) immune checkpoint protein blockade, (2) adoptive transfer of cancer-reactive T lymphocytes, and (3) use of novel agents to modify the cancer microenvironment so that the immune system can more effectively eliminate the disease. In 2017, Dr. Johnson was named Director of the BMT & Cell Therapy Lab at MCW. This laboratory serves the combined pediatric and adult Blood & Marrow Transplant Program at MCW by processing all hematopoietic progenitor cell products, as well as providing services for several novel cell therapeutics. Currently, the lab is generating a novel CAR T cell product (CD19-CD20 dual CAR T cells) for a first-in-human phase 1 clinical trial to treat adults with treatment-refractory lymphomas.